Related Experiment Video

Updated: Jun 18, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects

William T Cefalu1, Robert J Richards, Lydia Y Melendez-Ramirez

  • 1Joint Program on Diabetes, Endocrinology and Metabolism, Louisiana State University Health Science Center, New Orleans, LA, USA. cefaluwt@pbrc.edu

Cleveland Clinic Journal of Medicine
|December 3, 2009
PubMed

Insights

Type 2 diabetes mellitus (T2DM) management requires addressing core defects and comorbidities. Newer agents like glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors offer improved glycemic control and potential cardiovascular benefits.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Disease Research
  • Public Health

Background:

  • Type 2 diabetes mellitus (T2DM), obesity, and cardiovascular disease (CVD) pose significant global health challenges.
  • Traditional T2DM pathophysiology focused on insulin resistance and secretion; emerging research highlights the role of incretin hormones.
  • Comprehensive T2DM management must address underlying defects and comorbidities, including blood glucose, blood pressure, weight, and lipid control.

Purpose of the Study:

  • To review the evolving understanding of T2DM pathophysiology, incorporating incretin hormone roles.
  • To discuss the comprehensive management of T2DM, including comorbidities and sequelae.
  • To evaluate newer antidiabetic agents and their potential impact on cardiovascular risk markers.

Main Methods:

  • Literature review of T2DM pathophysiology and treatment strategies.
  • Analysis of current and emerging antidiabetic pharmacotherapies.
  • Examination of clinical data on incretin-based therapies and cardiovascular outcomes.

Main Results:

  • Incretin hormones play a crucial role in T2DM progression.
  • Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors target fundamental T2DM defects.
  • These newer agents show promise in improving glycemic control and potentially mitigating cardiovascular risk factors.

Conclusions:

  • A multifaceted approach is essential for effective T2DM and comorbidity management.
  • GLP-1 receptor agonists and DPP-4 inhibitors represent significant advancements in T2DM pharmacotherapy.
  • Further research may necessitate redefining treatment success in T2DM based on emerging data and comprehensive patient outcomes.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...